多索茶碱与氨茶碱对COPD患者的临床效果及安全性分析

Safety and Efficacy of Doxofylline and Aminophylline in COPD Patients

关键词:  多索茶碱  氨茶碱  慢性阻塞性肺疾病  有效性  安全性

Key words:  doxofylline  aminophylline  chronic obstructive pulmonary disease(COPD)  efficacy  safety

摘要:

目的 探讨多索茶碱与氨茶碱对慢性阻塞性肺疾病(chronic obstructive pulmonary diseases，COPD)患者的临床效果与安全性。方法 选择瑞安市中医院2012年10月—2014年1月接诊的120例COPD患者的临床资料，将所有接诊患者按随机数字表分为2组，观察组60例，采用多索茶碱治疗，对照组60例，采用氨茶碱治疗，比较2组患者的安全性和有效性。结果 治疗后，观察组总有效率为98.33%，明显高于对照组，组间比较差异具有统计学意义(P<0.05)；观察组肺活量(VC)、用力肺活量(FVC)、最大通气量占预计值的百分比(MVV%)、最大呼气中期流量(MMF)、用力呼气25%肺活量时流速(PEF25)等肺功能指标均较对照组明显改善，组间比较差异具有统计学意义(P<0.05)；观察组不良反应发生率为3.33%，明显低于对照组，组间比较差异具有统计学意义(P<0.05)。结论 多索茶碱治疗COPD具有十分显著的疗效，且安全可靠，有利于患者的预后恢复，值得临床应用。

Abstract:

OBJECTIVE To investigate the safety and efficacy of doxofylline and aminophylline for COPD patients. METHODS All of 120 patients with COPD were included in the study, of which control group of 60 patients were treated with aminophylline, and the observation group of 60 patients were treated with doxofylline. The safety and efficacy of the two groups were compared. RESULTS After treatment, the total effective rate in the observation group was 98.33%, significantly higher than control group(P<0.05); the lung function index of VC, FVC, MVV%, MMF, PEF25 in observation group had significantly improved than control group(P<0.05); the incidence of adverse reactions in observation group was 3.33%, significantly lower than the control group(P<0.05). CONCLUSION Doxofylline in the treatment of COPD has a very significant effect, and it is worthy of clinical application.